Skip to main content

Table 4 Local infection as an adverse event vs. baseline

From: Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

  Occurrence of local infection as adverse event Total
Yes No
Local infection as baseline Yes 52 1270 1322
No 15 358 373
Total   67 1628 1695
  1. Information on baseline infection was missing in one subject with local infection as adverse event and in 90 subjects without it. The OR was 0.98; 95% CI: 0.54–1.76.